Chemotherapy · 2008 · 10 citations · 16 references
MedicineOncologyPharmacologyCancer Drug Toxicity ManagementChemotherapyClinical PharmacologyDose Adjustment In OncologyDose SelectionPharmacokinetics Of Anticancer DrugsToxicity ManagementChemotherapy Dose-limiting ToxicityDose-limiting Toxicity Assessment
BACKGROUND: We conducted a single-arm, dose-escalation, phase 1 clinical trial in order to define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of bexarotene in combination with docetaxel. METHODS: Patients with solid tumors and no other curative treatment options were eligible. Oral bexarotene was taken daily in combination with docetaxel 25 mg/m(2) administered intravenously on days 1, 8, and 15 of a 28-day cycle. The dose of bexarotene started at 200 mg/m(2) and increased by 100 mg/m(2)/dose level, until either a MTD or the final dose of 400 mg/m(2) was reached. RESULTS: Fifteen patients were enrolled in the study. Median age was 58 years. The majority had non-small-cell lung cancer. The study went to completion without reaching an MTD. Hematological toxicities were mild. Three patients developed grade 3 hypertriglyceridemia, all occurring during the first cycle of treatment. No objective responses were noted. Four patients had stable disease as a best response, 3 with non-small-cell lung cancer and 1 with angiosarcoma. CONCLUSIONS: Treatment was well tolerated and no DLT was seen at docetaxel 25 mg/m(2) and bexarotene 400 mg/m(2). Given that stable disease was durable in 4 patients, future studies with this combination may be warranted.
16
Nuclear receptor that identifies a novel retinoic acid response pathway
David J. Mangelsdorf, Estelita S. Ong, Jacqueline A. Dyck et al. · Nature · 1990 · 1.5K citations
Kazimierz Roszkowski, Maciej Krzakowski, A P Smith et al. · Lung Cancer · 2000 · 309 citations
Medicine, Oncology, Pharmacology +16